Showing results (51-60 of 81) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.Blood|January 20, 2018
Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantationHeike Pfeifer, Katharina Raum, Sandra Markovic, et al.Haematologica|February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemiaNicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.Blood|November 1, 2014
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialDieter Hoelzer, Jan Walewski, Hartmut Döhner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.Pageof 9